JP2019529415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529415A5 JP2019529415A5 JP2019514720A JP2019514720A JP2019529415A5 JP 2019529415 A5 JP2019529415 A5 JP 2019529415A5 JP 2019514720 A JP2019514720 A JP 2019514720A JP 2019514720 A JP2019514720 A JP 2019514720A JP 2019529415 A5 JP2019529415 A5 JP 2019529415A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- combination drug
- imo
- cancer
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000011510 cancer Diseases 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 8
- 208000021039 metastatic melanoma Diseases 0.000 claims description 8
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 7
- 229960002621 pembrolizumab Drugs 0.000 claims description 7
- 229960005386 ipilimumab Drugs 0.000 claims description 6
- 230000002601 intratumoral effect Effects 0.000 claims description 5
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims 21
- 239000000556 agonist Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021170043A JP2022009200A (ja) | 2016-09-15 | 2021-10-18 | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394845P | 2016-09-15 | 2016-09-15 | |
| US62/394,845 | 2016-09-15 | ||
| US201762486738P | 2017-04-18 | 2017-04-18 | |
| US62/486,738 | 2017-04-18 | ||
| PCT/US2017/051742 WO2018053242A1 (en) | 2016-09-15 | 2017-09-15 | Immune modulation with tlr9 agonists for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021170043A Division JP2022009200A (ja) | 2016-09-15 | 2021-10-18 | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529415A JP2019529415A (ja) | 2019-10-17 |
| JP2019529415A5 true JP2019529415A5 (OSRAM) | 2020-11-05 |
| JP7200093B2 JP7200093B2 (ja) | 2023-01-06 |
Family
ID=61620152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514720A Active JP7200093B2 (ja) | 2016-09-15 | 2017-09-15 | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
| JP2021170043A Pending JP2022009200A (ja) | 2016-09-15 | 2021-10-18 | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021170043A Pending JP2022009200A (ja) | 2016-09-15 | 2021-10-18 | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10463686B2 (OSRAM) |
| EP (1) | EP3512499A4 (OSRAM) |
| JP (2) | JP7200093B2 (OSRAM) |
| KR (1) | KR20190096936A (OSRAM) |
| CN (1) | CN110114057A (OSRAM) |
| AU (1) | AU2017325981A1 (OSRAM) |
| CA (1) | CA3036978A1 (OSRAM) |
| IL (2) | IL292658A (OSRAM) |
| MX (1) | MX2019002925A (OSRAM) |
| WO (1) | WO2018053242A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2750608T3 (es) | 2013-07-25 | 2020-03-26 | Exicure Inc | Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| JP7200093B2 (ja) | 2016-09-15 | 2023-01-06 | アイデラ・ファーマシューティカルズ，インコーポレーテッド | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
| KR102576042B1 (ko) | 2016-10-11 | 2023-09-07 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| KR102372274B1 (ko) | 2017-05-19 | 2022-03-08 | 우시 바이올로직스 (상하이) 컴퍼니 리미티드 | 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체 |
| WO2020081986A1 (en) * | 2018-10-18 | 2020-04-23 | Idera Pharmaceuticals, Inc. | Tlr9 modulators for treating cancer |
| KR20210087454A (ko) * | 2018-11-01 | 2021-07-12 | 파론 파머수티컬스 오와이 | 대체 활성화되는 대식세포 상의 clever-1 발현을 억제하는데 사용하기 위한 tlr9 작용제 |
| CA3123050A1 (en) | 2018-12-26 | 2020-07-02 | City Of Hope | Activatable masked anti-ctla4 binding proteins |
| JP2023517330A (ja) * | 2020-03-09 | 2023-04-25 | ダイナヴァックス テクノロジーズ コーポレイション | 破傷風、ジフテリア、および百日咳に対する能動的追加免疫付与 |
| EP4216930A4 (en) * | 2020-09-22 | 2024-08-07 | Trisalus Life Sciences, Inc. | CANCER THERAPY WITH TOLL-LIKE RECEPTOR AGONISTS |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2381993A1 (en) | 1999-08-13 | 2001-02-22 | Hybridon, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| JP4188687B2 (ja) | 2000-12-27 | 2008-11-26 | ダイナバックス テクノロジーズ コーポレイション | 免疫変調ポリヌクレオチド及びその使用法 |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| DK1575977T3 (da) * | 2002-12-23 | 2009-11-09 | Dynavax Tech Corp | Oligonukleotider med Immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| EP1631576A4 (en) | 2003-06-11 | 2010-08-25 | Idera Pharmaceuticals Inc | STABILIZED IMMUNOMODULATION OLIGONUCLEOTIDES |
| CN100482673C (zh) | 2003-07-15 | 2009-04-29 | 艾德拉药物股份有限公司 | 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用 |
| EP2363141A1 (en) | 2003-07-15 | 2011-09-07 | Idera Pharmaceuticals, Inc. | Compsition comprising two oligonucleotides linked directly at their 3'ends wherein at leat one oligonucleotide has an accessible 5'end and the compound further comprising IL-2 used for synergistically stimulating an immune response in a patient. |
| US7498425B2 (en) | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| EP2901856B1 (en) | 2004-06-15 | 2017-08-09 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| CN101268101A (zh) | 2005-07-07 | 2008-09-17 | 科利制药集团公司 | 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗 |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| CN101379195B (zh) | 2005-12-20 | 2012-05-09 | 艾德拉药物股份有限公司 | 含有不同长度回文片段的回文免疫调节性寡核苷酸(imotm)的免疫刺激活性 |
| US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
| WO2008073959A2 (en) | 2006-12-12 | 2008-06-19 | Idera Pharmaceuticals, Inc. | Synthetic agonists of tlr9 |
| ES2585239T3 (es) | 2007-08-01 | 2016-10-04 | Idera Pharmaceuticals, Inc. | Nuevos agonistas sintéticos de TLR9 |
| EP2391718A2 (en) | 2009-01-30 | 2011-12-07 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| WO2011100295A2 (en) | 2010-02-09 | 2011-08-18 | Medical College Of Georgia Research Institute, Inc. | Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase |
| PT3023788T (pt) | 2010-05-14 | 2020-05-18 | Massachusetts Gen Hospital | Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores |
| FR2975600B1 (fr) * | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| WO2013043647A1 (en) * | 2011-09-19 | 2013-03-28 | The Johns Hopkins University | Cancer immunotherapy |
| WO2014047085A2 (en) | 2012-09-20 | 2014-03-27 | Rongfu Wang | Prostate-specific tumor antigen and uses thereof |
| TWI660739B (zh) | 2013-10-25 | 2019-06-01 | 製藥公司 | 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法 |
| IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| IL251669B2 (en) * | 2014-10-10 | 2023-02-01 | Idera Pharmaceuticals Inc | Cancer treatment using a tlr9 agonist with checkpoint inhibitors |
| CN107949397A (zh) | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
| BR112017025562A2 (pt) | 2015-05-29 | 2018-08-07 | Merck Sharp & Dohme Corp. | métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer |
| ES2752063T3 (es) | 2015-05-29 | 2020-04-02 | Dynavax Tech Corp | Administración intrapulmonar de agonistas polinucleotídicos del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón |
| JP7200093B2 (ja) | 2016-09-15 | 2023-01-06 | アイデラ・ファーマシューティカルズ，インコーポレーテッド | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
-
2017
- 2017-09-15 JP JP2019514720A patent/JP7200093B2/ja active Active
- 2017-09-15 AU AU2017325981A patent/AU2017325981A1/en not_active Abandoned
- 2017-09-15 EP EP17851589.6A patent/EP3512499A4/en not_active Withdrawn
- 2017-09-15 IL IL292658A patent/IL292658A/en unknown
- 2017-09-15 CN CN201780067972.4A patent/CN110114057A/zh active Pending
- 2017-09-15 WO PCT/US2017/051742 patent/WO2018053242A1/en not_active Ceased
- 2017-09-15 CA CA3036978A patent/CA3036978A1/en active Pending
- 2017-09-15 US US15/705,631 patent/US10463686B2/en not_active Expired - Fee Related
- 2017-09-15 MX MX2019002925A patent/MX2019002925A/es unknown
- 2017-09-15 KR KR1020197010562A patent/KR20190096936A/ko not_active Ceased
-
2019
- 2019-03-14 IL IL265370A patent/IL265370B/en unknown
- 2019-08-30 US US16/557,597 patent/US10835550B2/en not_active Expired - Fee Related
- 2019-08-30 US US16/557,630 patent/US10772907B2/en not_active Expired - Fee Related
-
2020
- 2020-09-14 US US17/020,355 patent/US20210052625A1/en not_active Abandoned
- 2020-10-21 US US17/076,677 patent/US11224611B2/en active Active
-
2021
- 2021-10-18 JP JP2021170043A patent/JP2022009200A/ja active Pending
- 2021-12-06 US US17/543,341 patent/US20220088054A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529415A5 (OSRAM) | ||
| Lanitis et al. | Targeting the tumor vasculature to enhance T cell activity | |
| JP6858558B2 (ja) | 新生物疾患の処置、減少、阻害、又は制御において使用するための、免疫調節薬 | |
| US20210069147A1 (en) | Pharmaceutical combination and uses thereof | |
| ES2904880T3 (es) | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 | |
| US20210299187A1 (en) | Cancer therapy | |
| Schmittnaegel et al. | Reprogramming tumor blood vessels for enhancing immunotherapy | |
| Nakajima et al. | Synergistic antitumor activity of the novel SN‐38‐incorporating polymeric micelles, NK012, combined with 5‐fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5‐fluorouracil | |
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| JP2016530280A5 (OSRAM) | ||
| Raben et al. | Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model | |
| JP2016521712A5 (OSRAM) | ||
| JP2022189827A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2019508433A5 (OSRAM) | ||
| JPWO2020111018A5 (OSRAM) | ||
| JP2018518539A (ja) | がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム | |
| De Sanctis et al. | Molecular mechanisms of chloroquine and hydroxychloroquine used in cancer therapy | |
| JP2016524611A5 (OSRAM) | ||
| Manley et al. | A phase 1/2 dose‐finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system | |
| Sindhu et al. | L-asparaginase-mediated Therapy in L-asparagine Auxotrophic Cancers: A Review | |
| MX2014005087A (es) | Conjugados de lipido en el tratamiento de la rinosinusitis cronica. | |
| Attia et al. | A phase 1b dose-escalation study of TRC105 (anti-Endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS) | |
| Piha-Paul et al. | 723 A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti–PD1 and anti–LAG-3 antibody, in patients with select advanced malignancies | |
| Veiby et al. | 329 The investigational drug MLN0264 First-in-human, first in class ADC targeting GCC: phase I Dose-escalation study and supportive scientific rationale | |
| US20220096436A1 (en) | Combination product for the treatment of cancer |